icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies
 
 
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
 
Stuart C. Gordon,1 William J. Towner,2 Avanish M. Aggarwal,3 Julie Ma,4 John McNally,4 Luisa M. Stamm,4 Diana M. Brainard,4 William T. Symonds,4 John G. McHutchison,4 Nicholas Bellos,5 Karen T. Tashima,6 Nezam H. Afdhal7 1Henry Ford Health System, Detroit, Michigan, USA; 2Kaiser Permanente, Los Angeles, California, USA; 3Central Florida Gastroenterology, Orlando, Florida, USA; 4Gilead Sciences, Inc., Foster City, California, USA; 5Southwest Infectious Disease, PA, Dallas, Texas, USA; 6The Miriam Hospital, Providence, Rhode Island, USA; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif